Human papillomavirus type 16 E6 protein (HPV16 E6)

Human papillomavirus type 16 E6 protein (HPV16 E6) is a potent viral oncoprotein essential for the initiation and maintenance of the malignant phenotype in HPV-infected cells [1]. Its primary oncogenic function is the degradation of the host tumor suppressor protein p53 through the recruitment of the E6-associated protein (E6AP) ubiquitin ligase, which effectively bypasses DNA damage checkpoints and prevents apoptosis [2]. Beyond p53, HPV16 E6 also activates telomerase (hTERT) to promote cellular immortality and interacts with PDZ-domain proteins to disrupt cell polarity and signaling [3]. Because E6 is a non-self viral protein constitutively expressed in cancer cells but absent in healthy tissue, it represents an ideal target for therapeutic vaccines and adoptive T-cell therapies [4]. Current clinical strategies focus on inducing E6-specific CD8+ T-cell responses to selectively eliminate HPV16 E6-expressing cells in patients with cervical and oropharyngeal malignancies [5]. Experimental approaches also include small molecules and CRISPR/Cas9 systems designed to disrupt the E6-p53 interaction or silence E6 expression to restore natural tumor suppressive pathways [6].

Other names

HPV16 E6-expressing cellsHPV-16 E6Human papillomavirus type 16 early protein 6E6 oncoprotein

Therapeutic vaccines and T-cell therapies target HPV16 E6-expressing cells by inducing a cytotoxic T-lymphocyte (CTL) response against E6-derived peptides presented on MHC class I molecules [5, 6]. Experimental small molecules and PROTACs aim to disrupt the E6-E6AP interaction to stabilize p53, while RNA interference and CRISPR/Cas9 approaches target the E6 oncogene directly to induce senescence or apoptosis in malignant cells [6].